Copyright 2013 Wolters Kluwer Health Lippincott Williams Wilkins Monoamine

Copyright 2013 wolters kluwer health lippincott

This preview shows page 16 - 24 out of 31 pages.

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Monoamine Oxidase Inhibitors (MAOIs) (cont.) Actions Irreversibly inhibits MAO, allowing norepinephrine, serotonin, and dopamine to accumulate in the synaptic cleft Indications Treatment of patients with depression who are unresponsive to, or unable to take other antidepression agents Pharmacokinetics Absorbed from GI tract Peak 2-3 hours Metabolized in the liver, excreted in the urine Cross placenta and enter breast milk
Image of page 16
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Monoamine Oxidase Inhibitors (MAOIs) (cont.) ContraindicationsKnown allergy, pheochromocytoma, CV disease, headaches, renal or hepatic impairmentAdverse ReactionsDizziness, excitement, nervousness, mania, hyperreflexia, tremors, confusion, insomnia, agitation, liver toxicity, nausea, vomiting, diarrhea or constipation, anorexia, weight gain, dry mouth, and abdominal pain
Image of page 17
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Monoamine Oxidase Inhibitors (MAOIs) (cont.) Drug-to-Drug Interactions Other antidepressants Hypertensive crisis, coma Methyldopa Sympathomimetic effects increase Insulin or oral antidiabetic agents Additive hypoglycemia Food Interactions Tyramine or pressor amines Increase blood pressure
Image of page 18
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Prototype MAOI s Agent
Image of page 19
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Nursing Considerations for MAOI Antidepressant Agents Assessment: History and Physical Exam Nursing Diagnosis Implementation Evaluation
Image of page 20
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Question Please answer the following statement as true or false. MAOIs are generally prescribed for people with depression who respond to safer drugs.
Image of page 21
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins AnswerFalseRationale: The MAOIs are generally indicated for treatment of the signs and symptoms of depression in patients who can not tolerate or do not respond to other, safer antidepressants.
Image of page 22
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Selective Serotonin Reuptake Inhibitors (SSRIs)
Image of page 23
Image of page 24

You've reached the end of your free preview.

Want to read all 31 pages?

  • Summer '16
  • Selective serotonin reuptake inhibitor, Antidepressant, Tricyclic antidepressant, Wolters Kluwer Health, Lippincott Williams & Wilkins

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture